Vergent Bioscience has launched the Phase 3 VISUALIZE 2 trial evaluating abenacianine, a tumor-activated imaging agent designed to enhance intraoperative tumor detection in lung cancer surgery. The ...
Engineered Oncolytic Virus Reprograms Immunity and Extends Survival in Brain Cancer ...